We are a precision oncology company pioneering the development of cancer therapies. Guided by Foresight, our proprietary functional genomics platform, we are deeply rooted in science and innovation with the vision to compassionately contribute to solving cancer.

Learn More

Who we are:

Fore was founded in 2011 as NovellusDx. We focus on people with genetically defined cancers, whose current treatment options are limited.

Our Approach

We are in the business of life. We aim to evolve the biotech model by harnessing the best of science and innovation, within and outside our walls. Our mission is to find and match the right therapies for the right patients with the hardest to treat cancers, and provide access in the most expeditious and high quality manner.

Our Foresight Engine

With our integrated functional genomics and machine learning drug discovery engine, we synthesize a wide range of mutations across validated oncological targets and in-license clinical stage small molecule assets to develop for hyper-targeted patient populations.

Our Lead Program

Our lead program, PLX-8394, a promising next generation treatment for Class I/II BRAF mutations, is an advanced investigational drug in Ph I/II trials, which was identified by our platform for its inhibitory effect across a wide range of unique BRAF mutations.

Management Team

Usama Malik
Chief Executive Officer
Michael Vidne, PhD
Gabi Tarcic, PhD
Chief Technology Officer
Zohar Barbash, PhD
VP Research
Yaron Shimon, CPA
VP Finance & Operation
Steven Averbuch, MD
Executive Clinical & Regulatory Advisor
Kathe Balinski, RN, MA, MSJ
Executive Clinical Operations Advisor
David R. Kronenthal, Ph.D
Lead CMC Advisor

Board of Directors

Dieter Weinand
Industry Expert, Chairman
Erez Chimovits
Senior Managing Director at Orbimed
Tomer Kariv
Partner at Pontifax
Chandra Leo
Partner at HBM Partners
Matthew Foy
Partner at SR One
Michal Silverberg
Managing Director at NVF
Roberto De Ponti
Head of Strategic Investments at Helsinn
Usama Malik
Chief Executive Officer

Scientific Advisory Board

Steven Averbuch, MD
Executive Clinical & Regulatory Advisor, Head of the SAB
Filip Janku, MD
SAB Member
David Solit, MD
SAB Member
Brian Schwartz, MD
SAB Member

Key Investors

Learn More

For more information, please see the following press release or download our corporate presentation.

Get in touch

Yaron Shimon, CPA
VP Finance & Operation
+972 (0) 25956597